![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Shattuck Labs Inc | NASDAQ:STTK | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.12 | 2.78% | 4.43 | 3.98 | 5.69 | 4.54 | 4.36 | 4.37 | 167,132 | 01:00:00 |
Presentation DetailsConference: 42nd Annual J.P. Morgan Healthcare ConferencePresenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive OfficerDate: Thursday, January 11, 2024Time: 12:00 p.m. PT Location: Westin St. Francis, San Francisco, CA
A live webcast of the presentation will be available on the Events & Presentations section of the Company’s website. A replay of the webcast will be archived for up to 30 days following the presentation date.
About Shattuck Labs, Inc.Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, (“ARC®”), platform are designed to simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company’s lead SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
Investor & Media Contact: Conor RichardsonVice President of Investor RelationsShattuck Labs, Inc.InvestorRelations@shattucklabs.com
1 Year Shattuck Labs Chart |
1 Month Shattuck Labs Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions